While clearly disappointing for the SP, would love to hear your thoughts on the rationale for an expanded NSCLC (TACTI--002) and new HNSCC (TACTI-003) trial?
with NSCLC - with additional 74 participants - is this a pathway to accelerated approval without then going through a Phase 3 (so almost a Phase 2b)? With possible results in Q1 2022, this could be a quicker way to going to market?
Interesting though about HNSCC (TACTI-003). The announcement only mentions "efti in combination with an anti-PD-1 treatment, or anti-PD-1 monotherapy". So bringing in a new partner?
Ann: Immutep completes a A$29.6 million placement, page-16
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $1.817M | 5.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71665 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 36363 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |